Consulting Services
For Investors
Products
Case Studies
Insights

Contact Us

Search

HERCULES

Neuroscience

Neuroscience Weekly News - September 24th 2025

🧠 This Week in Neuroscience: Ocrelizumab Safety, MAVENCLAD Durability, ECTRIMS…

Neuroscience

Neuroscience Weekly News - September 17th 2025

🧠 This Week in Neuroscience: RNAi Tau Therapy CTA, MS Patent Win, Generic…

Categories

Obesity News
Endocrinology News
Our Insights
Immunology News
Case studies
Hematology News
BioPharma and Tech News
Oncology News
BioPharma Strategy, CI and AI Guides
Lucid Diligence Brief
Conference Social Media Reports
Venture Capital Trends
AI in Healthcare and Digital Health
Conference Previews
Cell and Gene Therapy News
Healthcare and Pharma Trends
Rare Disease News
Health Mobile Apps Reports
Neuroscience News
LucidWargames case studies by LucidQuest
Women's Health News
LucidScope AI Audit Analyses by LucidQuest
Public Health News
Monthly Strategic Roundups
Respiratory News
Cardiovascular News
Vaccine news

Recent Posts

Obesity Strategic Roundup: Emerging Competition | Oct 5 – Nov 6 , 2026
ACR 2026 Preview: CAR-T, Emerging Immune Therapies and AI in Rheumatology
AHA Scientific Sessions 2026 Preview: Cardiovascular Outcomes, Emerging Therapies and AI
Cardiovascular Strategic Roundup: Device Innovation and Treatment Value | Oct 01 – Nov 04, 2026
Evestia Clinical Acquires Emtex Life Science | Lucid Diligence Brief

Tags

AAV Gene Therapy ACC 2025 ACLF ailux Autosomal Dominant Polycystic Kidney Disease Ayumi Pharmaceutical Holdings biotech diligence Blinatumomab cholera commercial launches Dexamethasone EGFR Exon 20 Insertion Elecsys pTau181 Fanconi anemia geneventiv therapeutics GMP Biotechnology Googlebook graft-versus-host disease GSK Canada GSK Nuvalent acquisition Headache Alliance IAS 2025 idiopathic pulmonary fibrosis market Lebrikizumab Major depressive disorder MK-1084 mursla bio narcolepsy treatment market nvidia Obesity drug market trends PCSK9 inhibitor Polyrizon Primary Plasma Cell Leukemia ProFound Therapeutics progressive multiple sclerosis RNAi therapeutics roflumilast 0.05% Saol Therapeutics SS Innovations Surgical retina SynphaBase Taiho Pharmaceutical TCT Universal Vaccines ViraxImmune

Archives

Archives

LucidQuest Ventures

Accelerate Your Success

LATEST NEWS

Obesity Strategic Roundup: Emerging Competition | Oct 5 – Nov 6 , 2026
ACR 2026 Preview: CAR-T, Emerging Immune Therapies and AI in Rheumatology
AHA Scientific Sessions 2026 Preview: Cardiovascular Outcomes, Emerging Therapies and AI
Cardiovascular Strategic Roundup: Device Innovation and Treatment Value | Oct 01 – Nov 04, 2026
Evestia Clinical Acquires Emtex Life Science | Lucid Diligence Brief

TAGS

AAV Gene Therapy ACC 2025 ACLF ailux Autosomal Dominant Polycystic Kidney Disease Ayumi Pharmaceutical Holdings biotech diligence Blinatumomab cholera commercial launches Dexamethasone EGFR Exon 20 Insertion Elecsys pTau181 Fanconi anemia geneventiv therapeutics GMP Biotechnology Googlebook graft-versus-host disease GSK Canada GSK Nuvalent acquisition Headache Alliance IAS 2025 idiopathic pulmonary fibrosis market Lebrikizumab Major depressive disorder MK-1084 mursla bio narcolepsy treatment market nvidia Obesity drug market trends PCSK9 inhibitor Polyrizon Primary Plasma Cell Leukemia ProFound Therapeutics progressive multiple sclerosis RNAi therapeutics roflumilast 0.05% Saol Therapeutics SS Innovations Surgical retina SynphaBase Taiho Pharmaceutical TCT Universal Vaccines ViraxImmune

Consulting Services
For Investors
Products
Case Studies
Insights

© 2026 LucidQuest Ventures. All rights reserved

We use cookies from third party services to offer you a better experience. Read about how we use cookies and how you can control them by clicking "Privacy Preferences".

Privacy Preference Center

Privacy Preferences

When you visit any website, it may store or retrieve information on your browser in the form of cookies. Since we respect your right to privacy, you can choose not to permit data collection from certain types of services. However, not allowing these services may impact your experience ans we are able to offer you.

Privacy Policy

Required

You read and agreed to our Privacy Policy

Tracking

We use third-party cookies that help us analyze and understand how you use this website. These cookies do not store any personal information.

Privacy Policy